Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: Evidence for drug safety, tolerance, and antiviral activity

Journal of Infectious Diseases

Volumn 173, Issue 5, 1996, Pages 1107-1114

  Skillman, Donald R ^a,c   Malone, Joseph L ^a   Decker, Catherine F ^a   Wagner, Kenneth F ^a   Mapou, Robert L ^a   Liao, Mei June ^b   Testa, Douglas ^d   Meltzer, Monte S ^e  

^a Interferon Sciences Inc ^*

^b Interferon Sciences Inc   (United States)

^c FITZSIMONS ARMY MEDICAL CENTER   (United States)

^d AAG Incorporated   (United States)

^e KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAN3 INTERFERON; CD4 ANTIGEN; NEUTRALIZING ANTIBODY;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SELF ADMINISTRATION; DRUG TOLERANCE; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PERMISSIBLE DOSE; NEUROPSYCHOLOGICAL TEST; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0029944112     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.5.1107     Document Type: Article

References (11)

1. Ho DD, Hartshorn KL, Rota TR, et al. Recombinant human interferon alpha-A suppresses HTLV-III replication in vitro. Lancet 1985;1:-602-4.
2. Koyanagi Y, O'Brien WA, Zhao JO, Golde DW, Gasson JC, Chen ISY. Cytokines alter production of HI V-1 from primary mononuclear phagocytes. Science 1988;241:1673-5.
3. Kornbluth RS, Oh PS, Munis JR, Cleveland PH, Richman DD. Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro. J Exp Med 1989;169:1137-51.
4. Poli G, Orenstein JM, Kinter A, Folks TM, Fauci AS. Interferon-α but not AZT suppresses HIV expression in chronically infected cell lines. Science 1989;244:575-7.
5. Laurence J. Immunology of HIV infection, I: biology of the interferons. AIDS Res Hum Retroviruses 1990;6:1149-56.
6. Gendelman HE, Baca LM, Turpin JA, et al. Regulation of HIV replication in infected monocytes by IFN-α: mechanisms for viral restriction. J Immunol 1990;145:2669-76.
7. Fernie BF, Poli G, Fauci AS. Alpha interferon suppresses virion but not soluble human immunodeficiency virus antigen production in chronically infected T-lymphocytic cells. J Virol 1991;65:3968-71.
8. Pitha PM. Multiple effects of interferon on HIV-1 replication. J Interferon Res 1991;11:313-8.
9. Francis ML, Meltzer MS, Gendelman HE. Interferons in the persistence, pathogenesis, and treatment of HIV infection. AIDS Res Hum Retroviruses 1992;8:199-207.
10. Hansen BD, Nara PL, Maheshwari RK, et al. Loss of infectivity by progeny virus from interferon-treated human immunodeficiency virus type 1-infected T cells is associated with defective assembly of envelope gp120. J Virol 1992;66:7543-8.
11. Krown SE. The role of interferon in the therapy of epidemic Kaposi's sarcoma. Semin Oncol 1987;14:27-33.